波士頓科學收購SoniVie，擴充心臟介入治療產品組合

美通社

2025/03/05

(醫藥健聞2025年3月5日訊）波士頓科學公司宣佈，已簽訂對私營醫療器械公司SoniVie Ltd.的最終收購協議，這家公司開發了TIVUS血管內超聲系統。TIVUS系統是一項處於試驗階段的技術，旨在通過對血管周圍神經進行去神經支配，治療多種高血壓疾病，包括針對高血壓的經腎動脈去交感神經術（RDN）。

此次收購將憑藉用於治療高血壓的經腎動脈去交感神經療法，擴充心臟介入治療產品組合。

作為 SoniVie 的戰略投資者，波士頓科學目前持有約 10% 的股權。因此，此次交易包括為尚未持有的 90% 股權支付約 3.6 億美元的首付款，以及在達到特定法規審批里程碑時最高可達 1.8 億美元的款項。

海量資訊、精準解讀，盡在新浪財經APP

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2517824954"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517824954\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2517824954?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-03-05 11:46","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2517824954","market":"sh","top_or_hot":-1,"title":"波士頓科學收購SoniVie，擴充心臟介入治療產品組合","media":"美通社","content":"<html><body><div>\n<p cms-style=\"font-L\">(醫藥健聞2025年3月5日訊）<a href=\"https://laohu8.com/S/BSX\">波士頓科學</a>公司宣佈，已簽訂對私營醫療器械公司SoniVie Ltd.的最終收購協議，這家公司開發了TIVUS血管內超聲系統。TIVUS系統是一項處於試驗階段的技術，旨在通過對血管周圍神經進行去神經支配，治療多種高血壓疾病，包括針對高血壓的經腎動脈去交感神經術（RDN）。</p><p cms-style=\"font-L\">此次收購將憑藉用於治療高血壓的經腎動脈去交感神經療法，擴充心臟介入治療產品組合。</p><p cms-style=\"font-L\">作為 SoniVie 的戰略投資者，波士頓科學目前持有約 10% 的股權。因此，此次交易包括為尚未持有的 90% 股權支付約 3.6 億美元的首付款，以及在達到特定法規審批里程碑時最高可達 1.8 億美元的款項。</p><div><img src=\"http://n.sinaimg.cn/spider20250305/450/w750h500/20250305/87e8-ae78bd3de2afb4e96fb384866cdc0ffd.jpg\"/><span></span></div>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n</div></body></html>","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>波士頓科學收購SoniVie，擴充心臟介入治療產品組合</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n波士頓科學收購SoniVie，擴充心臟介入治療產品組合\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">美通社</strong><span class=\"h-time small\">2025-03-05 11:46</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<p cms-style=\"font-L\">(醫藥健聞2025年3月5日訊）<a href=\"https://laohu8.com/S/BSX\">波士頓科學</a>公司宣佈，已簽訂對私營醫療器械公司SoniVie Ltd.的最終收購協議，這家公司開發了TIVUS血管內超聲系統。TIVUS系統是一項處於試驗階段的技術，旨在通過對血管周圍神經進行去神經支配，治療多種高血壓疾病，包括針對高血壓的經腎動脈去交感神經術（RDN）。</p><p cms-style=\"font-L\">此次收購將憑藉用於治療高血壓的經腎動脈去交感神經療法，擴充心臟介入治療產品組合。</p><p cms-style=\"font-L\">作為 SoniVie 的戰略投資者，波士頓科學目前持有約 10% 的股權。因此，此次交易包括為尚未持有的 90% 股權支付約 3.6 億美元的首付款，以及在達到特定法規審批里程碑時最高可達 1.8 億美元的款項。</p><div><img src=\"http://n.sinaimg.cn/spider20250305/450/w750h500/20250305/87e8-ae78bd3de2afb4e96fb384866cdc0ffd.jpg\"/><span></span></div>\n<div></div>\n<div>\n<div><img src=\"\"/></div>\n<div>海量資訊、精準解讀，盡在新浪財經APP</div>\n</div>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.sina.com.cn/stock/usstock/c/2025-03-05/doc-inenqpat1990106.shtml\">美通社</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1989764664.SGD","symbol_name":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-03-05/doc-inenqpat1990106.shtml","article_id":"2517824954","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517824954","pubTimestamp":1741146360,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"波士頓科學公司宣佈，已簽訂對私營醫療器械公司SoniVie Ltd.的最終收購協議，這家公司開發了TIVUS血管內超聲系統。TIVUS系統是一項處於試驗階段的技術，旨在通過對血管周圍神經進行去神經支配，治療多種高血壓疾病，包括針對高血壓的經腎動脈去交感神經術。此次收購將憑藉用於治療高血壓的經腎動脈去交感神經療法，擴充心臟介入治療產品組合。作為 SoniVie 的戰略投資者，波士頓科學目前持有約 10% 的股權。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU2506952170.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) INC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","BK4082":"医疗保健设备","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0823417653.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","BK4504":"桥水持仓","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4588":"碎股","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4581":"高盛持仓","LU2506951875.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) ACC","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0823417737.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","BK4585":"ETF&股票定投概念","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BSX":"波士顿科学"},"translate_title":"Boston Scientific Acquires SoniVie, Expands Cardiac Interventional Portfolio","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1},"content_text":"(醫藥健聞2025年3月5日訊）波士頓科學公司宣佈，已簽訂對私營醫療器械公司SoniVie Ltd.的最終收購協議，這家公司開發了TIVUS血管內超聲系統。TIVUS系統是一項處於試驗階段的技術，旨在通過對血管周圍神經進行去神經支配，治療多種高血壓疾病，包括針對高血壓的經腎動脈去交感神經術（RDN）。此次收購將憑藉用於治療高血壓的經腎動脈去交感神經療法，擴充心臟介入治療產品組合。作為 SoniVie 的戰略投資者，波士頓科學目前持有約 10% 的股權。因此，此次交易包括為尚未持有的 90% 股權支付約 3.6 億美元的首付款，以及在達到特定法規審批里程碑時最高可達 1.8 億美元的款項。\n\n\n\n海量資訊、精準解讀，盡在新浪財經APP","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}